Telintra-Revlimid Combo May Help Lower-Risk MDS Patients
 

From the MDS Beacon...

Telintra-Revlimid Combination May Be Effective And Safe In Lower-Risk MDS Patients
by Jessica Langholtz

Results from a Phase 1 clinical trial suggest that the combination of Telintra and Revlimid may be effective and safe in lower-risk myelodysplastic syndromes patients.

The study investigators found that the combination of Telintra and Revlimid promoted the growth of new blood cells. In addition, several patients who were previously dependent on red blood cell transfusions became transfusion-independent after therapy.

For the rest, see the article at MDS Beacon.

Here's the related eligible terms to participate in future upcoming clinical trials...

"Ages Eligible for Study:18 Years and older

Genders Eligible for Study:Both

Accepts Healthy Volunteers:no

Criteria: Inclusion Criteria: - Histologic diagnosis of primary or de novo MDS using WHO classification - Non-del(5q) low or Intermediate-1risk MDS - ECOG performance status of 0-1 - Documented significant cytopenia for at least 2 months - Must have discontinued growth factors (EPO, G-CSF, GM-CSF) for at least 21 days prior to study entry - All study participants must be registered into the mandatory RevAssist® program and be willing and able to comply with the requirements of RevAssist® - Females of childbearing potential should have two negative serum pregnancy tests with a sensitivity of at least 50 mIU/mL. The first test should be performed within 10-14 days, and the second test within 24 hours of prescribing lenalidomide (prescriptions must be filled within seven days) Exclusion Criteria: - Known hypersensitivity to Telintra™ (intravenous or oral) - Known prior therapy with or hypersensitivity to thalidomide or lenalidomide - Prior allogenic bone marrow transplant for MDS - History or prior malignancy - Except for treated carcinoma of uterine cervix, basal cell or squamous cell skin cancer, or other cancers (e.g. breast, prostate) for which patient has been disease-free for at least 3 years. - MDS evolving from: - A pre-existing myeloproliferative disorder - An autoimmune disease - Secondary to prior treatment with radiation or chemotherapy - History of MDS IPSS score>1.0 - Pregnant or lactating women - Leptomeningeal or leukemic meningitis - Prior treatment with DNA methyltransferase inhibitors (DMTI) [e.g., azacitadine, decitabine, etc.]" :cool: